Aimmune ' s Peanut Allergy Drug Meets Main Goal, Shares Surge Aimmune ' s Peanut Allergy Drug Meets Main Goal, Shares Surge

U.S. drug developer Aimmune Therapeutics Inc said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study, sending its shares up 18 percent premarket.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news